Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
50 hedge funds and large institutions have $91M invested in Merrimack Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 14 increasing their positions, 9 reducing their positions, and 7 closing their positions.
72% more call options, than puts
Call options by funds: $6.79M | Put options by funds: $3.96M
56% more repeat investments, than reductions
Existing positions increased: 14 | Existing positions reduced: 9
43% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 7
12% more capital invested
Capital invested by funds: $81.2M → $91M (+$9.8M)
6% more funds holding
Funds holding: 47 → 50 (+3)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAP
Madison Avenue Partners
New York
|
+$6.5M |
| 2 |
Invesco
Atlanta,
Georgia
|
+$2.47M |
| 3 |
WSL
Western Standard LLC
Los Angeles,
California
|
+$1.68M |
| 4 |
NM
Newtyn Management
New York
|
+$1.24M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$1.15M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
2L
22NW LP
Seattle,
Washington
|
-$11.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.52M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$1.37M |
| 4 |
O
OrbiMed
New York
|
-$843K |
| 5 |
PVI
Pura Vida Investments
New York
|
-$735K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
O
51
OrbiMed
New York
| – | -$843K | -73,600 | Closed |
|
|
PVI
52
Pura Vida Investments
New York
| – | -$735K | -64,100 | Closed |
|
53
Two Sigma Investments
New York
| – | -$487K | -42,490 | Closed |
|
54
Two Sigma Advisers
New York
| – | -$128K | -11,181 | Closed |
|
|
FWA
55
Freedom Wealth Alliance
Brookfield,
Wisconsin
| – | -$20.9K | -1,820 | Closed |
|
56
JP Morgan Chase
New York
| – | -$4K | -354 | Closed |
|
MACK Hedge Fund Activity: Q1 2023 in Review
50 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q1 2023, worth a combined $91M — up 12% from $81.2M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new MACK positions and 7 closed out — a net gain of 3 holders — while 14 added to existing stakes and 9 trimmed.
The largest buyer was Madison Avenue Partners, opening a new position worth an estimated $6.5M. The largest seller was 22NW LP, exiting entirely with an estimated $11.6M sold.
- 50 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q1 2023, up from 47 in Q4 2022.
- Funds reported $91M of Merrimack Pharmaceuticals, Inc. stock for Q1 2023, up 12% quarter-over-quarter.
- 10 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q1 2023 and 7 closed out, a net change of +3 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q1 2023 was Madison Avenue Partners, an estimated $6.5M added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q1 2023 was 22NW LP, an estimated $11.6M sold.
Based on aggregated 13F filings for Q1 2023.